Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

PLXBullishEarningsShort Term

High materiality9/10

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

StockNews.AIAug 12, 6:50 AM EDT1 source

Trading thesisImportance 9/10

Long PLX with 12–18 month horizon on topline PRX-115 results and extended Elfabrio IP moat.

AI summary

What happened and why it matters

Protalix BioTherapeutics posted strong Q2 2026 results, with revenues from selling goods of $19.8 million and year-to-date revenue of $53.6 million, aided by Elfabrio sales and a $25 million milestone from Chiesi. The company also reported net income of $22.1 million year-to-date and a cash balance of $40.7 million with no debt, while reaffirming 2026 guidance. Key near-term catalysts include the PRX-115 Phase 2 RELEASE topline due in 2H 2027 and ongoing IP protections that extend Elfabrio through 2035.

Elfabrio patent term extension to 2035 strengthens long-term IP moat.
Chiesi milestone payment of $25M boosts 2026 visibility.
Q2 revenue growth driven by Elfabrio and Fiocruz, with Pfizer purchases down YoY.
No debt and cash balance of $40.7M provides operational runway.

Sentiment rationale

stronger revenues, confirmed guidance, IP extensions, and a cash-rich balance sheet support higher valuation; near-term upside potential from PRX-115 topline and Elfabrio moat.

Key facts

01
Q2 2026 revenues from selling goods rose to $19.8M. Elfabrio drove growth globally.
02
YTD revenue $53.6M. Includes $25M Chiesi milestone.
03
YTD net income $22.1M. Cash $40.7M.
04
Elfabrio patent term extension to 2035; Korea orphan designation.
05
PRX-115 RELEASE Phase 2 enrollment continues; topline in 2H 2027.

Earnings

Category: Earnings. The release combines quarterly results with business updates and pipeline milestones, anchoring the stock on near-term topline momentum and IP durability rather than a single product launch.